Search research articles
Contact Us
Filters
Showing results (41-50 of 49) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 49 results.
Journal of Primary Care & Community Health
|
July 30, 2025
Improved Depression Symptoms Among Low-Income Mexican Americans Participating in a Community-Clinical Diabetes Intervention
MinJae Lee, Joseph H Conroy, Zihan Yang, et al.
British Journal of Cancer
|
July 25, 2013
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
A H Ko, M A Tempero, Y-S Shan, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
January 11, 1991
Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats
C G Yeh, H C Marsh, G R Carson, et al.
Cancer Research Communications
|
September 26, 2025
Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer
Chi M Nguyen, Paul G Yeh, Mai P Nguyen, et al.
Journal of Medicinal Chemistry
|
June 20, 1998
(+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist
X Cai, R T Scannell, D Yaeger, et al.
Preventive Medicine
|
April 30, 2024
An expanded chronic care management approach to multiple chronic conditions in Hispanics using community health workers as community extenders in the Rio Grande Valley of Texas
Juliana Z Lopez, MinJae Lee, Soo K Park, et al.
Cancer Chemotherapy and Pharmacology
|
January 12, 2015
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
T C Chang, H S Shiah, C H Yang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 15, 2013
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
A C Roy, S R Park, D Cunningham, et al.
Science Translational Medicine
|
September 26, 2014
Clinical recovery from surgery correlates with single-cell immune signatures
Brice Gaudillière, Gabriela K Fragiadakis, Robert V Bruggner, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 49) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 49 results.
Journal of Primary Care & Community Health
|
July 30, 2025
Improved Depression Symptoms Among Low-Income Mexican Americans Participating in a Community-Clinical Diabetes Intervention
MinJae Lee, Joseph H Conroy, Zihan Yang, et al.
British Journal of Cancer
|
July 25, 2013
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
A H Ko, M A Tempero, Y-S Shan, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
January 11, 1991
Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats
C G Yeh, H C Marsh, G R Carson, et al.
Cancer Research Communications
|
September 26, 2025
Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer
Chi M Nguyen, Paul G Yeh, Mai P Nguyen, et al.
Journal of Medicinal Chemistry
|
June 20, 1998
(+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist
X Cai, R T Scannell, D Yaeger, et al.
Preventive Medicine
|
April 30, 2024
An expanded chronic care management approach to multiple chronic conditions in Hispanics using community health workers as community extenders in the Rio Grande Valley of Texas
Juliana Z Lopez, MinJae Lee, Soo K Park, et al.
Cancer Chemotherapy and Pharmacology
|
January 12, 2015
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
T C Chang, H S Shiah, C H Yang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 15, 2013
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
A C Roy, S R Park, D Cunningham, et al.
Science Translational Medicine
|
September 26, 2014
Clinical recovery from surgery correlates with single-cell immune signatures
Brice Gaudillière, Gabriela K Fragiadakis, Robert V Bruggner, et al.
Page
of 5